Overview

A Single-arm Prospective Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma

Status:
Recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of post-marketing Regiorense injection secondary infusion in the treatment of adult patients with relapsed or refractory B-cell lymphoma.
Phase:
Phase 4
Details
Lead Sponsor:
Ruijin Hospital